24 - 26 August 2023 | Westin, Perth

Program

The ANZCHOG ASM 2022 program will include plenary sessions, invited speaker sessions, industry involvement and concurrent paper sessions.

As more details of the program and speakers are confirmed, this page will be updated. Refer back to this page regularly for updates. Please note that the program is subject to change.

The pre-ASM nursing workshop is included with the Full ASM Delegate registration type. Space for this workshop is limited and you will need to indicate during the registration process if you would like to attend.

Venue: Hyde Park Room, Sheraton Grand Hyde Park, Sydney

0900-1630

ANZCHOG Nurses Pre Conference Workshop Program

0900-0905
Welcome & housekeeping
0905-0950

The importance of self-care and the impact of the pandemic

Dr Justin Baker

St Jude Children’s Research Hospital

0950-1035
Hiding in plain sight. Nursing’s superpower

Prof Mei Krishnasamy
Peter MacCallum Cancer Centre
1035-1055
Morning tea
1055-1120
Genomics for everyone

Dr Kim Alexander
Queensland University of Technology
1120-1145
Haemophilia overview and what’s the treatment plan for 2022

Grainne Dunne
Sydney Children’s Hospital
1145-1210
Fertility and emerging therapies

Tejnei Vaishnav
Royal Hospital for Women, NSW
1210-1230
The role and value of the research nurse

A/Prof Natalie Bradford
Queensland University of Technology
1230-1300
Lunch
1300-1430
What’s on your eLearning wishlist? eviQ Education showcase and workshop
1430-1450

The Druggle, Improving Paediatric Oncology Drug Knowledge in Real Time

Ms Genevieve Daly
Kids Cancer Centre, Sydney Children's Hospital

1450-1505
Afternoon tea
1505-1535
Navigating end-of-life conversations with adolescents and young adults using the Australian Voicing My Choices tool: best practice & case examples

Dr Ursula Samson Daly, Cath O’Dwyer & Fiona Maguire
Sydney Children’s Hospital
1535-1605
Children and Adolescents with Cancer: Neuropsychological effects, education needs and interventions
Dr Soheil Afshar
Sydney Children’s Hospital

1605-1635

Health and wellbeing after cancer: a multidisciplinary program for long-term survivors of childhood malignancies

Dr Christina Signorelli, Karen Johnston & Rachael Bell
Sydney Children’s Hospital
1635-1700

ANZCHOG Nurses Update, Evaluations and Close

Brought to you by

You will have the option to register your attendance to the Parent Program during the registration process for the ASM.

If you would like to attend the virtual Parent Program only please proceed via the standard registration portal and use registration code*: PAR22 when prompted in order to bypass the ASM registration.

*Please note, by using this code, you will not be registered to attend the ASM or any of the social functions.

Example

0930-1510
Parent Program
Chair: Donna Drew
0930-0935
Welcome and house keeping for virtual attendees
0935-0955
Keeping up with school during and after childhood cancer

Joanna Fardell

0955-1015

Managing social challenges during and after childhood cancer

Clarissa Schilstra
1015-1030
Questions
1030-1045
Morning tea
1045-1115

When your child has cancer, goals of care, hope and compassion

Justin Baker

1115-1145
Minimising the psychological impact of cancer treatment on children and adolescents

Liane Willis
1145-1215
Questions
1215-1300
Lunch
Chair: Joanna Fardell
1300-1320
Staying fit and active during and after cancer

Lauren Ha
1320-1340
Managing the needs of siblings who have a brother or sister with cancer

Brittany McGill
1350-1400
Afternoon tea
1400-1420
When and how do I talk to my child about their cancer experience : side effects, experience, fertility

Tali Foreman
1420-1440
Survivor’s Story: Clarissa will share her story about her cancer diagnosis, relapse, survivorship, academic achievements and being a mum

Clarissa
1500-1510
Summary of the day & close
0900-0915
Opening ceremony
0915-1015
Plenary 1

Chair: Dr Richard Mitchell

Dr Justin Baker
St Jude Children’s Research Hospital

1015-1045
Morning tea - Trade display and poster viewing
1045-1130
Plenary 2

Chair: Dr Richard Mitchell

Old drugs and new: Still so much to learn about haemostasis in children
Prof Paul Monagle
Kids Cancer Centre, Sydney Children's Hospital/University of Melbourne

1130-1215
Plenary 3

Chair: Dr Richard Mitchell

Fertility preservation in young people: The new standard of care
A/Prof Antoinette Anazodo
Kids Cancer Centre, Sydney Children's Hospital

1215-1315
Lunch - Trade display and poster viewing
1245-1315
Partner lunch symposium 1
Prof Selim Corbacioglu
Children's Hospital Regensburg Germany


Brought to you by
1315-1445
Concurrent 1: Non malignant haematology
Concurrent 2: Solid tumours
Concurrent 3: Patient experience

Chair: Prof Paul Monagle

Current management of sickle cell disease
Dr Anthea Greenway
Royal Children's Hospital Melbourne

Iron deficiency anaemia
Prof Sant-Rayn Parischa
Walter and Eliza Hall Institute of Medical Research

Transfusion medicine
Dr Gemma Crighton

Royal Children's Hospital Melbourne

Chair:

Current therapies in neuroblastoma
Dr Toby Trahair
Kids Cancer Centre, Sydney Children's Hospital

A Comprehensive Patient-Derived Xenograft Model Platform to Support Translational Neuroblastoma Research
Dr Jamie Fletcher
Children's Cancer Institute

A novel paediatric oncology mouse clinic
Ms Zahra Abbas
Telethon Kids Institute

Targeting the Anti-apoptotic Protein BCL2 With Venetoclax Combination Treatment in High-risk Neuroblastoma
Ms Madeleine Wheatley
Children's Cancer Institute

Exploiting Arginine Addiction to Treat High-Risk Neuroblastoma
Dr Kimberley Hanssen
Children's Cancer Institute

Chair: Donna Drew

Hoping against hope - Supporting hope in advancing illness
Dr Justin Baker
St Jude Children's Hospital Memphis

ASSET: Collecting patient toxicity data and quality of life data together, where to next?
Dr Joanna Fardell
Kids Cancer Centre, Sydney Children's Hospital

Do long term survivors adhere to recommendations provided by MDT review?
Dr Jordana McLoone
Kids Cancer Centre, Sydney Children's Hospital

Developing a model of care for AYA patients with culturally diverse backgrounds
Dr Azhani Amiruddin
Crown Princess Mary Cancer Centre

1445-1515
Afternoon tea - Trade display and poster viewing
1445-1700
Concurrent 4: Non malignant haematology
Concurrent 5: Solid tumours
Concurrent 6: Patient experience

Chair: Prof Paul Monagle

Novel treatments of ITP
Dr Sally Campbell
Royal Brisbane &Women's Hospital

 

Current care in haemophilia
Janine Furmedge
Royal Children's Hospital Melbourne

 

National guidelines for ITP
Dr Tina Carter & Dr Vanessa Verissimo
Perth Children's Hospital 

Chair: Dr Felicity Wright

Paediatric and adolescent thyroid cancer
A/Prof Antoinette Anazodo
Kids Cancer Centre, Sydney Children's Hospital

Promoting positive physical activity behaviours in children and adolescents undergoing acute cancer treatment: feasibility of the CanMOVE intervention
Ms Sarah Grimshaw
Murdoch Children's Research Institute

Recruitment principles and strategies for supportive care research in pediatric oncology
A/ Prof Natalie Bradford
Queensland University of Technology

The outcome of pediatric extracranial malignant germ cell tumors: ten years experience of a single institution in Southern Vietnam
Dr T. T. An Dao
University of Medicine and Pharmacy At Ho Chi Minh City

Chair: Chrissy Hanmore

Health workers' understanding of and barriers to palliative care services for Aboriginal children with cancer
Dr Sophie Jessop
Kids Cancer Centre SCH

Identifying education and employment outcomes and support needs in Adolescents and Young Adults diagnosed with cancer
A/ Prof Pandora Patterson / Jennifer Cohen
Canteen, Australia

Fathers’ Experiences of Childhood Cancer
Ms Jenny Davies
Curtin University

“Torn in Two” Experiences of mothers who are pregnant when their child is diagnosed with cancer
Ms Jenny Davies
Curtin University

Home-Based Hydration for Chemotherapy – Its Clinical Impact and the Experience of Paediatric Oncology Patients and Their Families
Mrs Jennifer Arguelles
Paediatric Integrated Cancer Service

The management of pain for children hospitalised during Haematopoietic Stem Cell Transplantation
Dr Karin Plummer
Griffith University

1700-1900
Welcome reception
0730-0830
Partner breakfast 1
Partner breakfast 2
Partner breakfast 3

Brought to you by

Brought to you by

0900-1000
Plenary 4

Chair: Prof Claire Wakefield

You should ask that: The different faces of life after treatment

Dr Robert Battisti
Children's Hospital Westmead

1000-1030
Morning tea - Trade display and poster viewing
1030-1130

ANZCHOG 2022 Best abstracts

Chair: Dr Richard Mitchell

Molecular monitoring of ctDNA in neuroblastoma patients for response monitoring and relapse prediction
Dr Vinod Vijay Subhash
Children's Cancer Institute

Cardio-oncology guidelines for paediatric oncology patients: A Delphi consensus approach to inform risk stratification, surveillance and management during active cancer therapy.
Mr Ben Felmingham
Murdoch Children's Research Institute

Generation and Multi-Dimensional Profiling of a Childhood Cancer Cell Line Atlas Defines New Therapeutic Opportunities
Dr Paul Daniel
Hudson Institute Of Medical Research

1130-1200

ANZCHOG foundations lecture

Chair: Prof Les White

A history of paediatric stem cell transplantation in Australia

Prof Marcus Vowels

1200-1330
Lunch - Trade display and poster viewing
1230-1300
Partner lunch symposium 2
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer

Professor David Ziegler
Kids Cancer Centre

Theodore W. Laetsch, MD
Children’s Hospital of Philadelphia/University of Pennsylvania

Brought to you by

1300-1430
Concurrent 7: Neuro-oncology
Concurrent 8: Precision medicine
Concurrent 9: Global oncology in Oceania: A joint SIOP-ANZCHOG symposium across disciplines

Chair: Dr Neevika Manoharan

A/Prof Jordan Hansford
Women's and Children's Hospital Adelaide

Epigenetic regulation of innate signaling in brain tumors: Implications for novel therapeutic approaches.
Dr David M. Ashley
Duke University

Preliminary Analysis of the Pharmaco-phospho-proteo-genomic Landscape of Paediatric High-grade Gliomas
Mr Izac Findlay
University Of Newcastle

Determining the Clinical Utility of the Immune Modulating Antibody Anti-CD47 in a Preclinical Model of Medulloblastoma.
Dr Meegan Howlett
Telethon Kids Institute

Chair: Dr Karen McCleary

Precision Medicine 101
Dr Loretta Lau
Kids Cancer Centre SCH

High-Throughput Drug Testing on Patient-Derived Models Identifies Novel Rational Treatment Options for Paediatric Cancer Patients
Dr Emmy Dolman
Children's Cancer Institute

Precision medicine is changing the roles of healthcare professionals, scientists, and research staff: Learnings from a childhood cancer precision medicine trial.
Ms Rebecca Daly
UNSW

Chairs: Professor Claire Wakefield & Dr Michael Sullivan

1430-1500
Afternoon tea - Trade display and poster viewing
1500-1630
Concurrent 10: Neuro-oncology
Concurrent 11: Leukaemia/Cellular Therapy
Concurrent 12: ANZCHOG Trial & Research updates

Chair: Prof Richard Cohn

Long-term control and safety of larotrectinib in a cohort of adult and paediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumours
A/ Prof Jordan Hansford
WCHN

Australasian Methylation Array Profiling – an Update on the AIM BRAIN PROject
Dr Christine White
Victorian Clinical Genetics Services

Characteristics of Children with Brain Cancer: A 10-Year Retrospective Cohort
A/ Prof Natalie Bradford
Queensland University of Technology

Preclinical optimisation of the PI3K/AKT/mTOR inhibitor paxalisib for the treatment of diffuse intrinsic pontine glioma
Dr Ryan Duchatel
University Of Newcastle

Chair: Dr Adam Nelson

Cooperative deletions of key lymphoid transcription factors strongly associated with recurrent genomic lesions in B-cell acute lymphoblastic leukaemia
Ms Jacqueline Rehn
South Australian Health and Medical Research Institute

Vincristine-Induced Peripheral Neuropathy: Assessing Preventable Strategies in Paediatric Acute Lymphoblastic Leukemia.
Dr Benjamin Schreiber
Children's Cancer Institute

Reinventing The Wheel - Changing High Dose Methotrexate Habits
Dr Phoebe Power
Sydney Children's Hospital

Chimeric Antigen Receptor (CAR) T cell Therapy: Updated Outcomes at a Single Centre
Dr Seong Lin Khaw
Royal Children's Hospital Melbourne

Chair: Dr Maria Kirby
1630-1700
Meet the experts 1
Clinical use of asparaginase
Meet the expert 2
Dinutuximab beta as immunotherapy in high-risk neuroblastoma
Meet the expert 3

Dr Siobhan Cross
Canterbury District Health Board

Jessica Nicholson
Children's Health Queensland

Brought to you by

Dr Martin Campbell Royal Children’s Hospital Melbourne

Dr Aleksandra Wieczorek University Children’s Hospital, Krakow

Brought to you by
1900-2300
Gala dinner
0900-1100
Debate: When is enough enough? The role of phase 1 trials
Moderator: Annabel Crabb
ABC journalist
1100-1130
Morning tea - Trade display and poster viewing
1130-1230
Plenary 5
Dr Justin Baker
St Jude Children's Hospital Memphis
1230-1300
Closing ceremony
Day 1 - Thursday 28 July
1245 - 1315
Prof Selim Corbacioglu
Children's Hospital Regensburg Germany

Brought to you by

Day 2 - Friday 29 July
0730 - 0830
Brought to you by

Brought to you by

1230 - 1300
Partner Lunch Symposium 2
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer
Professor David Ziegler
Kids Cancer Centre

Theodore W. Laetsch, MD
Children’s Hospital of Philadelphia/University of Pennsylvania

Brought to you by

1630 - 1700
Meet the experts 1
Clinical use of asparaginase
Meet the experts 2
Dinutuximab beta as immunotherapy in high-risk neuroblastoma

Dr Siobhan Cross
Canterbury District Health Board

Jessica Nicholson
Children's Health Queensland

Brought to you by

Dr Martin Campbell
Royal Children’s Hospital Melbourne

Dr Aleksandra Wieczorek
University Children’s Hospital, Krakow

Brought to you by

BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

eviQ and eviQ Education are programs of the Cancer Institute NSW, a state government cancer control agency. Both programs have a national target audience and an international reach.

eviQ provides free online evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

eviQ Education provides free, evidence-based cancer eLearning resources for health professionals.

Vencare Medical

ECP made EASY! Flexible two-step ECP that works for you! info@vencaremedical.com.au

Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that is committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development.

Worldwide approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation, with half of that investment dedicated to research to help fight cancer.
Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier Australia is also home to the Asia-Pacific clinical trial hub.
Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. For further information see the website www.servier.com.au

Servier Australia’s oncology products include Oncaspar (pegaspargase), Lonsurf® (trifluridine/tipiracil) and Onivyde® (nanoliposomal irinotecan as sucrosofate).

A/Prof Antoinette Anazodo

Kids Cancer Centre, Sydney Children’s Hospital

A/Professor Anazodo is the lead clinician for Youth Cancer Services in NSW and the ACT, and the Director of the Adolescent and Young Adult Cancer Service encompassing Sydney Children’s Hospital and Prince of Wales Hospital. She leads the Future Fertility research program and has been instrumental in making fertility preservation accessible for oncology patients all around Australia, by developing Medicare item numbers for public funding. A/Professor Anazodo chairs the Australian AYA fertility preservation group, which leads the development of guidelines in the field of oncofertility. She has over 100 publications in the fields of adolescent medicine and oncofertility, and is a principle investigator on multiple successful grants from both the NHMRC and Cancer Australia. A/Professor Anazodo has received a number of awards for her work including a NSW Premiers award in 2018 and a Medal of the Order of Australia in 2021.

Dr Justin Baker

St Jude Children’s Research Hospital

Dr Baker is the Division Chief of Quality of Life and Palliative Care at St. Jude Children’s Research Hospital, Memphis, TN, USA. He is trained in paediatric haematology/oncology, as well as Hospice and Palliative Medicine. Dr Baker is a world leader in paediatric palliative care and quality of life, with over 100 publications in the field. His research focuses on integrating palliative care into the ongoing care of children with cancer, the ethical consideration of early phase trials, and paediatric palliative care in developing countries. He was awarded the AAHPM Inspirational Leader in Hospice and Palliative Medicine in 2014, and the St. Jude Communicator of the Year in 2017. Dr Baker has led the development of guidelines in paediatric palliative care and quality of life that have been implemented in centres throughout the world, and has been an invited speaker at paediatric oncology and palliative care conferences across the globe.

Dr Robert Battisti

Children’s Hospital Westmead

DR ROB BATTISTI | CLINICAL PSYCHOLOGIST | BPSYCH (HONS), PhD (CLINICAL PSYCHOLOGY) | FACPA | LEUT RAN

Rob Battisti is a Senior Clinical Psychologist and head of Psycho-oncology at the Cancer Centre for Children at the Children’s Hospital at Westmead and a Clinical Director at Mind Plasticity, a large multi-disciplinary mental health practice in Sydney. He is passionate about delivering evidence-based therapies and overcoming some of the traditional barriers that restrict people from accessing top quality care via team care arrangements. A key focus of his work is mental health service development, including policy, governance and clinical training. His goal in children’s cancer services is to ensure that mental wellness, education and future quality of life are placed firmly in the treatment mix.

Rob completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre (BMC) at the University of Sydney. He has worked in and around Sydney for many years and has professional affiliations with organisations such as the BMC, headspace and St Vincent’s Private Hospital. He has additionally served on the Board of Directors for the Australian Clinical Psychology Association (ACPA) of which he is a Fellow member.

Rob has expertise in working with individuals and families with more complex needs and in multi-disciplinary care arrangements. His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in cancer and other areas of health psychology, addiction, and psychiatric comorbidity (i.e. multiple diagnoses).

Rob also consults to organisations on preventative mental health and is a Lieutenant Psychologist with the Royal Australian Navy.

Prof Paul Monagle

University of Melbourne

Professor Monagle is an internationally renowned paediatric haematologist and haemato-pathologist. He is a Professor of Paediatrics at the University of Melbourne, a clinical Haematologist at the Kids Cancer Centre, Sydney Children’s Hospital, and an Honorary Fellow and Group Leader in Haematology Research at the Murdoch Children’s Research Institute. Professor Monagle is a world expert on thrombosis and coagulation, with over 300 publications in the field of paediatric haematology. His research group holds multiple NHMRC grants and is currently leading work into COVID-19 associated thrombosis. Professor Monagle was awarded the Outstanding Research Award in Paediatric Cardiology by the American Heart Association in 2008, and delivered the Barry Firkin Oration for the Thrombosis & Haemostasis Society of Australia and New Zealand in 2018. He has played a key role in designing multiple international multi-centre trials, and been an invited speaker at haematology conferences across the globe.

Prof Marcus Vowels

Professor Vowels is a renowned early leader of the paediatric oncology and haematology disciplines in Australia. Professor Vowels established the first bone marrow transplant program in Australia at the then Prince of Wales Children’s Hospital, now Sydney Children’s Hospital in Randwick, NSW. Professor Vowels established the Australian Cord Blood Bank and was a founding trustee of the Australian Cord Blood Foundation. Professor Vowels has over 100 peer reviewed publications, he was the founding member of a number of editorial boards of discipline specific journals and is the author of multiple book chapters. Professor Vowels was the President of the Australian and New Zealand Children’s Cancer Study Group from 1990 to 1994, and was awarded a Member of the Order of Australia (AM) for his service to medicine, particularly in the fields of childhood leukaemia and cancer.

Annabel Crabb

ABC Journalist

Annabel Crabb is one of Australia’s most beloved journalists. She is an ABC writer and presenter who has covered Australian politics for 20 years but also is nationally well-known for her insightful and humorous analysis on gender and current affairs. 

Annabel recently created and presented the ground breaking Ms Represented, unearthing stories from the 100 years of women in Australian parliaments. For the ABC, she has also devised and presented six seasons of the enormously popular Kitchen Cabinet, and “The House with Annabel Crabb – the fly-on-the-wall documentary on Australian Parliament.” She also presents the ABC’s hit culinary history series Back In Time For Dinner, and co-stars in Tomorrow Tonight with Charlie Pickering.

With friend and ABC colleague Leigh Sales, Australia’s pre-eminent current affairs journalist, Annabel hosts the top-rating podcast Chat 10 Looks 3. Their first book together, Well Hello, was published in September 2021.

Annabel is an avid baker and proud mother of three.

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.

For further information visit www.bayer.com.au

MISSION: WE CHANGE LIVES, PATIENT BY PATIENT

At EUSA we are committed to transforming the lives of people affected by cancer or rare disease, globally.

We continuously strive to uncover opportunities which address gaps across adult and paediatric care – through development opportunities, acquiring, and in-licensing therapies.

Helping the people with few or no options available is at the heart of everything we do at EUSA. Every day, we are proud to make a difference – building a company around our people, our values, and our mission.

We see a need. We work together. We don’t give up.

Breakthroughs That Change Patients’ Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Leukaemia & Blood Cancer New Zealand (LBC) is New Zealand’s national charity dedicated to supporting patients, and their families/whānau, living with a blood cancer or a serious blood condition.

The Robert Connor Dawes (RCD) Foundation was created in June 2013 in the memory of Robert ‘Connor Dawes’ who lost his 16-month battle with an ependymoma brain tumour at just 18 years of age. The RCD Foundation works to support brain matters projects in the areas of research, care and development – to fund the science to fight paediatric brain cancer and support patients in the meantime.

The Foundation operates in Australia and the US, and to date has invested $3.45M into paediatric brain cancer research, funding basic science and translational projects, as well as capacity building grants through fellowships, scholarships and travel grants. It has also leveraged another $10M, leading collaborative research initiatives. In addition to funding and partnering with Australian research institutes and Foundations, RCD is also active member of the Child’s Brain Tumour Network (CBTN), Paediatric Neuro-Oncology Consortium (PNOC) and the Collaborative Ependymoma Research Network (CERN). We leverage our research investments through partnering with like-minded and passionate organisations to continue to battle paediatric brain cancer.

Our history
The Kids’ Cancer Project is an independent national charity supporting childhood cancer research. Since 1993, the charity has contributed more than $50 million dollars to scientific research projects to help children with many different types of cancer.

Our Goal
Mission: To support bold scientific research that has the greatest chance of clinical success in the improvement of treatments of childhood cancers.

Vision: One hundred per cent survival for children with cancer while eradicating the harmful impacts treatment can bring.

What we stand for
Science: We believe the only way to improve outcomes for kids with cancer is through advances in medical research.

Solutions: Our research priorities reflect our focus on finding better treatments, building research capabilities and supporting survivorship programs.

Survival: Our founder, Col Reynolds OAM, made a promise
to never give up until a cure is found.

For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. As we move towards precision medicinein pediatric cancer, we have only just begun to discover the true impact of genomics. Learn how Illumina technologies is enabling novel insights into childhood cancer risk and treatment. Visit: https://sapac.illumina.com/destination/Precision-Medicine-in-Pediatric-Cancers.html

Jazz Pharmaceuticals is a global Biopharmaceutical Company whose purpose is to transform the lives of patients and their families through innovation. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options so they can live their lives more fully.

We have a diverse portfolio of marketed medicines and novel product candidates, from early- to latestage development, in Neuroscience and Haematology/Oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Jazz Pharmaceuticals has employees around the globe including Australia and New Zealand, serving patients in nearly 75 countries

Medical Information
Phone: 1800577422
Email: medinfo-apac@jazzpharma.com

Adverse event
Phone: 1800577422
Email: AEReporting@jazzpharma.com


To report a Product Complaint, please email:
productcomplaints@jazzpharma.com

A/Prof Jordan Hansford

Women’s and Children’s Hospital Adelaide

Jordan is a mid-career clinician specializing in the treatment of paediatric brain tumours. He has a long-standing interest in cancer genetics post the completion of his Master’s of Science in Cancer Genetics at Queen’s University, Canada. Upon the completion of his clinical training and admission to fellowship, he relocated to Melbourne where he led the team’s neuro-oncology and clinical research teams. Most recently he has relocated to Adelaide where he is developing a Neuro-Oncology research program at SAHMRI/SAiGENCI and the new Bragg Proton Radiotherapy Centre. He is currently the chair of the ANZCHOG brain group.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Novartis has more than 60 years’ history in Australia and employ around 600 associates across its two divisions.

At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.

Join the ANZCHOG ASM mailing list

Stay informed with the latest updates
* indicates required